Top Markets
#1 Islamic Coin Islamic Coin +154.50%
#2 PulseChain PulseChain +49.22%
#3 RedStone RedStone +23.91%
#4 MarsCoin MarsCoin +12.77%
#5 Nockchain Nockchain +12.59%
#6 BOOK OF MEME BOOK OF MEME +11.85%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.84%
#8 SkyAI SkyAI +8.96%
#9 Lighter Lighter +8.81%
#10 Monad Monad +8.69%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Immunotech Biopharm Ltd Immunotech Biopharm Ltd

Immunotech Biopharm Ltd

6978
Rank in Stocks #27877
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in... Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
Share Price
$0.04861197
Market Cap
$30.02M
Change (1 day)
0.00%
Change (1 year)
-91.39%
Country
CN
Trade Immunotech Biopharm Ltd (6978)

Category

Healthcare
Revenue for Immunotech Biopharm Ltd (6978)
Revenue in Aug 2026 TTM: 0
According to Immunotech Biopharm Ltd latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Immunotech Biopharm Ltd from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH